Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 17(2021), 22 vom: 20. Aug., Seite 2923-2939 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gounder, Mrinal [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 05.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2021-0284 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324106734 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324106734 | ||
| 003 | DE-627 | ||
| 005 | 20231225185618.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2021-0284 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324106734 | ||
| 035 | |a (NLM)33855868 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gounder, Mrinal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 05.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a advanced liposarcoma | |
| 650 | 4 | |a pain | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a progression-free survival | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a selective inhibitor of nuclear export | |
| 650 | 4 | |a selinexor | |
| 650 | 7 | |a Hydrazines |2 NLM | |
| 650 | 7 | |a Placebos |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a selinexor |2 NLM | |
| 650 | 7 | |a 31TZ62FO8F |2 NLM | |
| 700 | 1 | |a Abdul Razak, Albiruni R |e verfasserin |4 aut | |
| 700 | 1 | |a Gilligan, Adrienne M |e verfasserin |4 aut | |
| 700 | 1 | |a Leong, Hoyee |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Somaiah, Neeta |e verfasserin |4 aut | |
| 700 | 1 | |a Chawla, Sant P |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Broto, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Grignani, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Schuetze, Scott M |e verfasserin |4 aut | |
| 700 | 1 | |a Vincenzi, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Chmielowski, Bartosz |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Robin L |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Jatin |e verfasserin |4 aut | |
| 700 | 1 | |a Shacham, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Kauffman, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Riedel, Richard F |e verfasserin |4 aut | |
| 700 | 1 | |a Attia, Steven |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 17(2021), 22 vom: 20. Aug., Seite 2923-2939 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:22 |g day:20 |g month:08 |g pages:2923-2939 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2021-0284 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 22 |b 20 |c 08 |h 2923-2939 | ||